Register to join the KCSN
Menu

ESMO 2021: Sarcomatoid and/or rhabdoid RCC treated with immune checkpoint inhibitors after surgery

Cytoreductive nephrectomy is the surgical removal of the tumour to reduce the number of cancer cells (tumour burden), reduce the symptoms and immunosuppression caused by the tumour, and prevent complications. Recent studies have questioned the role of cytoreductive nephrectomy for patients with RCC that has spread (metastatic RCC). Metastatic sarcomatoid/rhabdoid clear cell RCC is an aggressive type of RCC that responds […]

Oct 01, 2021 / Comments Off on ESMO 2021: Sarcomatoid and/or rhabdoid RCC treated with immune checkpoint inhibitors after surgery / / Tags: , , ,
read more

Impact of cytoreductive nephrectomy in patients with metastatic kidney cancer

Cytoreductive nephrectomy is the removal of the tumour to reduce the number of cancer cells (tumour burden) and minimise the effects of a potentially immunosuppressive tumour, reduce the symptoms caused by the tumour, and prevent complications. During this study, overall survival was compared between patients with metastatic renal cell carcinoma (RCC) who were treated by […]

Dec 17, 2020 / Comments Off on Impact of cytoreductive nephrectomy in patients with metastatic kidney cancer / / Tags: , , ,
read more

Selection of advanced kidney cancer patients for nephrectomhy

In this study, 6,043 patients with metastatic renal cell carcinoma (RCC) had a nephrectomy while 489 did not and were follow-up. Age, stage, presence of metastases and tumour size were assessed. The study showed that there was no survival benefit for patients with stage T4 disease and metastases or older than 76 years of age […]

Oct 09, 2020 / Comments Off on Selection of advanced kidney cancer patients for nephrectomhy / / Tags: , , ,
read more

Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

A recent retrospective study (looking back at the patients’ cases after treatment had occurred) has shown that patients with metastatic renal cell carcinoma (RCC) who were treated with targeted therapy, such as sunitinib or pazopanib, or immunotherapy, such as nivolumab, had better survival outcomes if went on to have surgery to remove the kidney. This […]

Oct 05, 2020 / Comments Off on Surgery after targeted therapy or immunotherapy for metastatic kidney cancer / / Tags: , , , , , ,
read more

Evidence in favour of active surveillance for small renal masses

Two studies presented at the American Urological Association 2020 Virtual Experience this month provide evidence that active surveillance for small renal masses among older patients is as effective as surgery in terms of survival for patients with suspected renal cell carcinoma (RCC). In a study from Oxford University Hospitals 208 patients with 212 T1a small […]

May 18, 2020 / Comments Off on Evidence in favour of active surveillance for small renal masses / / Tags: , , , , , ,
read more

ASCO GU 2020: Nephrectomy linked to longer overall survival in patients treated with immunotherapy or targeted therapy for advanced kidney cancer

Surgery to remove the kidney tumour is often the preferred treatment for people with kidney cancer that has not spread. Recently, doctors have been questioning whether it is beneficial to operate to remove the kidney tumour in patients with kidney cancer that has already spread beyond the kidney. Immunotherapies for advanced kidney cancer include drugs […]

Feb 24, 2020 / Comments Off on ASCO GU 2020: Nephrectomy linked to longer overall survival in patients treated with immunotherapy or targeted therapy for advanced kidney cancer / / Tags: , , , , , ,
read more

Cytoreductive nephrectomy offers survival benefit in metastatic kidney cancer

The results of a trial looking at immunotherapy treatment with and without cytoreductive nephrectomy were presented at the 20th annual meeting of the Society of Urologic Oncology in Washington this week. The study included 391 patients diagnosed with metastatic renal cell carcinoma (RCC) between 2015 and 2016 from the National Cancer Data Base (NCDB). Of […]

Dec 06, 2019 / Comments Off on Cytoreductive nephrectomy offers survival benefit in metastatic kidney cancer / / Tags: , , ,
read more

ESMO 2019: Kidney cancer tumour shrinkage in patients who did not have surgery

This interview with Dr Monty Pal, Associate Professor from the City of Hope National Medical Center in California, USA discusses tumour shrinkage in patients who did not have a nephrectomy. The interview was conducted at the European Society of Medical Oncology (ESMO) 2019 conference in Barcelona earlier this month. Dr Pal discusses the results from […]

Oct 11, 2019 / Comments Off on ESMO 2019: Kidney cancer tumour shrinkage in patients who did not have surgery / / Tags: , , , , , , , ,
read more

Is there a role for cytoreductive nephrectomy?

This discussion with Dr Paul Russo presents a case for cytoreductive nephrectomy, despite the results from the CARMENA trial, which did not show an overall survival advantage. The report concludes that careful selection of patients with intermediate-risk (not poor-risk) metastatic renal cell carcinoma (RCC) and cytoreductive nephrectomy performed by experienced surgeons, followed by treatment with […]

Jun 27, 2019 / Comments Off on Is there a role for cytoreductive nephrectomy? / / Tags: , , ,
read more

The role of cytoreductive nephrectomy in metastatic kidney cancer

Around 12,500 new cases of renal cell carcinoma (RCC) are diagnosed annually in the UK, and about a third of these cases initially present with cancer that has spread to other parts of the body (non-localised or metastatic). Non-localised RCC has significantly worse 5-year survival outcomes compared with localised disease. The treatment options for patients […]

Jun 25, 2019 / Comments Off on The role of cytoreductive nephrectomy in metastatic kidney cancer / / Tags: , , , ,
read more
Showing 1 to 10 of 28 results
Web Design Cambridge Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
  TOP